Analysts are more bearish on Zhejiang Huahai Pharmaceutical'...

Analysts are more bearish on Zhejiang Huahai Pharmaceutical's future, reducing revenue and EPS estimates. The downgrade, coupled with high debt, hints at a potential business downturn.